On a fully diluted basis, $600mm is less than $5 pps, so, I seriously doubt that's the case. Berger has been nothing if not adamant about building a stand-alone oncology company. Perhaps at some point a buyout will happen but for now I'm more than happy to see Ariad's pipeline continue to develop. Imo, the Rida restructuring worked out well for both parties. MRK is now free to develop the drug more broadly thus potentially making ariad's "slice" of the pie bigger without the associated drain on capital resources that was delaying AP534 progress.
I know the buyout is coming but I do not know at what price.
I have seen this type of post on everyone of the 200 biotech stocks boards that I follow, yes one out of 50 small cap biotech stocks will be bought out in any given year. Also, you don't know that the buyout is coming & so your first post on Ihub is a "???".